March 21, 2013

Effect of Genzyme’s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies

In more than 70 percent of patients, disability scores improved or remained stable over three years

More than 80 percent of patients treated with LEMTRADA did not receive a third course of treatment in the first year of the extension

 

Effect of Genzyme’s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies
In more than 70 percent of patients, disability scores improved or remained stable over three years

Paris, France – March 21, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today interim results from the first year of the extension study of LEMTRADATM (alemtuzumab), being developed for the treatment for multiple sclerosis (MS).